Advertisement
Search for

Volume 8, Issue 2, Pages 206-212 (February 2010)


View previous. 32 of 40 View next.

Pathology Analysis Reveals That Dysplastic Pancreatic Ductal Lesions Are Frequent in Patients With Hereditary Pancreatitis

Vinciane ReboursCorresponding Author Informationemail address, Philippe Lévy, Jean–François Mosnier, Jean–Yves Scoazec§, Marie–Sophie Soubeyrand, Jean–François Fléjou, Bruno Turlin#, Pascal Hammel, Philippe Ruszniewski, Pierre Bedossa⁎⁎, Anne Couvelard⁎⁎

published online 17 September 2009.

Background & Aims

Hereditary pancreatitis (HP) is a risk factor for pancreatic adenocarcinoma. We performed a retrospective, multicenter study to characterize and evaluate the frequency of pancreatic intraepithelial neoplasia (PanIN) and to describe the characteristics of fibrosis in pancreatic surgical specimens from patients with HP.

Methods

Samples from partial pancreatectomies (n = 13) of patients with HP complications (n = 12; 7 males; mean age, 24 y; 1 patient underwent 2 surgeries over 16 years) were analyzed by histologic and immunohistologic analyses; patients with suspected or proven pancreatic adenocarcinoma were excluded. HP diagnosis was confirmed by analysis of PRSS1 mutations. Dysplastic lesions were described according to the PanIN classification.

Results

Eleven patients were found to have the R122H mutation in PRSS1 and 1 patient was found to have the N29I mutation in PRSS1. Fifty-one PanIN lesions were observed in 10 specimens (77%): PanIN lesions 1a, 1b, 2, and 3 were observed in 8, 5, 8, and 5 specimens, respectively. The median number of PanIN lesions was 3.5 for each specimen. The density of the lesions was 2.6 per 10 cm2. The size of lesions was greater than 0.5 mm in 55% of the samples. Two patients with PanIN-3 developed pancreatic cancer, 18 months and 44 years after surgery.

Conclusions

PanIN lesions are frequent, severe, and occur early in the course of HP. Among patients with PanINs, 50% had PanIN-3 lesions. Pancreatectomy could be considered as a prophylactic against pancreatic cancer in patients with high-grade dysplasia.

 Pôle des Maladies de l'Appareil Digestif, Service de Gastroentérologie–Pancréatologie, Hôpital Beaujon, AP-HP, Paris, Clichy, France

 Service de Pathologie et de Cytologie, Hôpital Hôtel Dieu, Nantes, France

§ Service de Pathologie, Hôpital Edouard Herriot, Lyon, France

 Laboratoire de Pathologie, Lyon, France

 Service de Pathologie, Hôpital Saint-Antoine, AP-HP, Paris, France

# Service de Pathologie, Hôpital Pontchaillou, Rennes, France

⁎⁎ Service de Pathologie, Hôpital Beaujon, AP-HP, Inserm U773-CRB3, Paris, Clichy, France

Corresponding Author InformationReprint requests Address requests for reprints to: Vinciane Rebours, MD, Pôle des Maladies de l'Appareil Digestif, Service de Gastroentérologie-Pancréatologie, Hôpital Beaujon, 100 Boulevard du Général Leclerc, 92110 Clichy Cedex, France. fax: (33) 01-42-70-37-84

 Conflicts of interest The authors disclose no conflicts.

PII: S1542-3565(09)00892-1

doi:10.1016/j.cgh.2009.09.009


View previous. 32 of 40 View next.

Advertisement